Piramal Pharma informs about updates
With reference to it letter dated 11th December, 2025 regarding US FDA Inspection at company’s manufacturing facility located at Lexington, (Kentucky, USA). Piramal Pharma has informed that US FDA has issued an Establishment Inspection Report (EIR) for the said manufacturing facility with VAI (Voluntary Action Indicated). Receipt of said EIR marks successful closure of the inspection. The intimation is being submitted today being the first working day after receipt of the said EIR.
The above information is a part of company’s filings submitted to BSE.
